

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

RIGEL PHARMACEUTICALS, INC.,

Petitioner,

v.

SERVIER PHARMACEUTICALS LLC

Patent Owner.

---

Case IPR2022-01423  
U.S. Patent No. 10,610,125

---

**DECLARATION OF DAVID H. SHERMAN  
IN SUPPORT OF PETITION FOR *INTER PARTES* REVIEW  
U.S. PATENT NO. 10,610,125**

**TABLE OF CONTENTS**

LIST OF EXHIBITS REFERENCED IN DECLARATION ..... iv

I. INTRODUCTION.....1

II. BACKGROUND AND QUALIFICATIONS .....2

III. MATERIALS CONSIDERED .....8

IV. MY UNDERSTANDING OF CERTAIN LEGAL STANDARDS .....9

    A. Ordinary Skill in the Art.....10

    B. Claim Construction.....10

    C. Anticipation (35 U.S.C. §102).....11

    D. Obviousness (35 U.S.C. §103) .....12

    E. Prior Art and Priority.....15

V. BACKGROUND.....17

    A. Overview of Technology .....17

    B. The '125 Patent.....18

    C. Technical Background and Prior Art.....25

        1. Parsons .....25

        2. Bleeker.....26

        3. Kang.....27

        4. Yan.....28

        5. Zhao .....29

        6. Mardis.....30

        7. Vogelstein.....32

        8. Dang 2009.....34

        9. Dang'243 .....37

        10. PM'678 .....37

11. PM 2012 .....	39
VI. A PERSON OF ORDINARY SKILL IN THE RELEVANT FIELD IN THE RELEVANT TIMEFRAME .....	44
VII. CLAIM CONSTRUCTION .....	46
VIII. SUMMARY OF MY OPINIONS .....	46
IX. THE CHALLENGED CLAIMS ARE INVALID .....	47
A. There can be no valid priority claim before July 13, 2013 .....	47
1. The state of the art as of March 2010 .....	48
2. The scope of the Challenged Claims is broad .....	51
3. The disclosure of the 2010 Application does not provide sufficient information to demonstrate possession of methods for treating IDH1-mutant AML .....	53
4. The scope of claims with respect to the small molecule inhibitor compounds is not supported by the 2010 application .....	61
5. Neither do the provisional applications support the Challenged Claims .....	72
6. There can be no valid priority date before July 11, 2013 .....	72
B. Ground 1: PM'678 anticipates the Challenged Claims .....	73
1. Claim 1 .....	73
2. Claims 2-5 .....	75
3. Claim 9-12 .....	76
C. Ground 2: PM 2012 in view of PM'678 renders obvious the Challenged Claims .....	78
1. Claim 1 .....	78
2. Claims 2-5 .....	80
3. Claim 9-12 .....	81
D. Ground 3: PM'678 (optionally together with PM 2012) in view of Dang'243 renders Challenged Claim 12 .....	83

E. Ground 4: Dang’243 Anticipates Claims 1-5 and 9-12 .....	84
1. Claim 1 .....	84
2. Claims 2-5.....	86
3. Claim 9-12 .....	87
X. NO SECONDARY CONSIDERATIONS.....	89
XI. CONCLUSION .....	89

**LIST OF EXHIBITS REFERENCED IN DECLARATION**

<b>Exhibit</b>	<b>Description</b>
1001	U.S. Patent No. 10,610,125 (“125 Patent”)
1002	Excerpted Prosecution History of U.S. Patent No. 10,610,125
1004	Curriculum Vitae of Professor David J. Sherman
1007	Mardis et al., <i>Recurring Mutations Found by Sequencing an Acute Myeloid Leukemia Genome</i> , 361 N. ENGL. J. MED. 1058 (2009). (“Mardis”)
1008	Vogelstein et al., U.S. Pat. App. Pub. No. 2011/0229479 (“Vogelstein”)
1009	Dang et al., Int’l Pat. App. Pub. No. 2010/105243 (“Dang ’243” or “2010 Application”)
1010	Popovici-Muller et al., Pat. App. Pub. No. 2012/009678 (“PM ’678”)
1011	Popovici-Muller et al., <i>Discovery of the First Potent Inhibitors of Mutant IDH1 That Lower Tumor 2-HG in Vivo</i> , 3 ACS MED. CHEM. LETT. 850 (2012). (“PM 2012”)
1012	Zhao et al. <i>Glioma-Derived Mutations in IDH1 Dominantly Inhibit IDH1 Catalytic Activity and Induce HIF-1<math>\alpha</math></i> , 324 SCIENCE 261 (2009).
1013	Tostmann et al., <i>Protecting Chemistry Inventions: The Double-Edged Sword of Being an Unpredictable Art</i> , 6 ACS MED. CHEM. LETT. 364-6 (2015).
1014	Golub et al., <i>Mutant Isocitrate Dehydrogenase Inhibitors as Targeted Cancer Therapeutics</i> , 9 FRONT. ONCOL. 417 (2019). (“Golub”)
1015	Parsons et al., <i>An Integrated Genomic Analysis of Human Glioblastoma Multiform</i> , SCIENCEEXPRESS (2008). (“Parsons”)
1016	Yan et al., <i>IDH1 and IDH2 Mutations in Gliomas</i> , 360 N. ENGL. J. MED. 765 (2009). (“Yan”)

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.